HiSiaddi is an innovative foreign trade service provider driven by dual pillars of technology transformation and foreign trade services, operating under the “1+2+3+4=1” integrated service framework, with direct access to original manufacturer supplies of Clostridium butyricum and Bacillus coagulans. With over a decade of market experience and deep collaboration with manufacturers on technology conversion projects, HiSiaddi maintains extensive expertise resolving regulatory compliance issues for these strains. Below is a case detailing HiSiaddi’s resolution of critical regulatory non-compliance risks for Clostridium butyricum and Bacillus coagulans.
Contact HiSiaddi customer service for additional regulatory compliance consulting for Clostridium butyricum and Bacillus coagulans products.
The partner client is NutriVita, a mid-to-high-end organic dietary supplement brand headquartered in France distributing premium products across Southern Europe including France, Spain and Italy. The brand specializes in organic-certified, gluten-free, non-GMO medical-grade probiotics with end-product retail prices ranging from EUR 60 to 180. All products strictly comply with EU Novel Food regulations, EFSA safety assessment standards, French AFNOR certification and EU Food Supplement Labeling Directive 2002/46/EC, enforcing extremely stringent requirements for strain regulatory eligibility, complete documentation packages and rigorous labeling standards.
In May 2026, the client planned bulk procurement of 10 Billion CFU/g Clostridium butyricum and 5 Billion CFU/g Bacillus coagulans raw materials for its new intestinal repair probiotic capsule line. After initial communications with two domestic Chinese manufacturers, the client encountered three critical roadblocks: unregulated strain eligibility, incomplete regulatory documentation and non-compliant labeling. Post-legal review by the client’s French legal team, the project was deemed high-risk for customs detention and blocked market launch, halting all procurement activities. The client urgently commissioned HiSiaddi to fully resolve all regulatory non-compliance issues, complete all missing documentation within 15 days and secure full alignment with EU and French regulatory standards, with failure risking permanent termination of Chinese supplier partnerships.
1. Fatal Risk: Strain Eligibility & Novel Food Regulatory Non-Compliance
· Clostridium butyricum: The originally proposed strain lacked EU Novel Food licensing, only supported by domestic Chinese feed-grade filings. French customs classified the strain as an unauthorized novel food, prohibiting import entry.
· Bacillus coagulans: The manufacturer provided ambiguous strain identifiers without official culture collection deposit numbers (DSM, ATCC), preventing cross-referencing against the EU QPS safety list and resulting in classification as an unidentified strain.
Core Conflict: Domestic manufacturers only provide China-focused regulatory filings without comprehension of EU strain entry criteria, failing to recognize that Clostridium butyricum requires standalone Novel Food authorization for EU market access.
1. Severe Regulatory Documentation Gaps (Guaranteed Customs Rejection) The client mandated complete English-language regulatory documentation packages, yet manufacturers only supplied Chinese business licenses and production permits, lacking mandatory filings including:
· Strain patent certificates, culture collection deposit proofs, EFSA-standard safety evaluation reports;
· Mandatory French market declarations: non-GMO (GMO-free), gluten-free and allergen-free statements;
· Notarized English versions of ISO 22000, HACCP and GMP certifications;
· Batch traceability records, English COA, heavy metal/microbial safety test reports aligned with EU standards.
Official French customs guidance confirms shipments lacking complete English documentation will face mandatory return to origin.
1. Non-Compliant Labeling & Prohibited Health Claims (Risk of Severe Post-Launch Fines) Raw material labels supplied by manufacturers only contained Chinese text labeling “Clostridium butyricum” and viable counts, violating three core EU labeling rules:
· Restricted terminology: The term “probiotic” constitutes an unauthorized health claim under EU regulations and is strictly prohibited on all labeling.
· Incomplete strain disclosure: Missing strain identifiers, culture collection deposit numbers, viable count units (CFU/g) and shelf-life data, violating Labeling Directive 2002/46/EC.
· Absence of EU responsible party: No designated EU-based importer/responsible entity listed, preventing registration with France’s national food regulatory authority.
The client’s French legal team warned labeling non-compliance post-launch carries maximum fines of EUR 100,000.
HiSiaddi assembled a dedicated cross-functional team of EU regulatory specialists, strain legislation experts and English document translation & notarization professionals, executing a four-stage remediation workflow: strain regulatory alignment → complete documentation compilation → labeling revision → customs pre-audit, fully aligned with EU and French regulatory benchmarks.
Non-compliant strains from original manufacturers were discarded; regulatory-validated strains from Qingdao Donghai Pharmaceutical were sourced as compliant alternatives:
· Clostridium butyricum CGMCC0313.1: Matches EU authorized strain specifications, complete strain origin documentation and safety evaluation reports provided.
· Bacillus coagulans TBC169: Registered DSM culture collection deposit number, listed on the EU QPS inventory, full non-GMO classification and comprehensive clinical safety data.
Official compliance statements issued confirming strain homology with EU authorized variants, with formal Novel Food compliance letters specifying exclusive dietary supplement use fully aligned with EU Regulation 2015/2283.
HiSiaddi coordinated manufacturers and third-party testing institutions to expedite drafting, English translation and official notarization of a complete EU-standard regulatory dossier, categorized into four core document groups:
1. Core Strain Documentation: Strain patent certificates, DSM/ATCC culture collection deposit proofs, EFSA-grade safety evaluation reports, toxicology & allergenicity testing reports.
2. Manufacturing Qualification Filings: Notarized English ISO 22000, HACCP and GMP certifications, FDA registration certificates, EU food facility registration numbers.
3. Safety Declaration Documents: Non-GMO statements, gluten-free declarations, allergen-free (dairy/soy absent) statements, animal-derived component negative certification.
4. Batch & Testing Documentation: English COA, full batch traceability records, EU-standard safety test reports (heavy metals, microbial contaminants, aflatoxins), factory inspection & quarantine certificates.
All documents bear manufacturer official stamps, HiSiaddi regulatory compliance seals and formal English notarization; post-review by the client’s French legal team, the dossier achieved 100% compliance eligibility for direct customs clearance and product registration.
HiSiaddi redesigned full English raw material labels adhering to three core regulatory principles:
1. Remove unauthorized health claims: Delete all instances of the restricted term “probiotic”, reclassified as “Compound Intestinal Support Strains” to only describe raw material composition without therapeutic efficacy promises.
2. Complete strain disclosure requirements: Explicit labeling of strain identifiers, culture collection deposit numbers, viable count (CFU/g), spore rate, production date, shelf life and storage conditions.
3. Traceability & responsible party disclosure: Full listing of EU importer name, physical address and contact information (local French regulatory responsible entity), country of origin (“Product of China”), batch numbers and traceability QR codes.
Revised labels passed pre-audit by French AFNOR certification bodies, fully compliant for direct application on end-product packaging.
HiSiaddi partnered with local French customs brokers to conduct full simulated regulatory audits covering three core review dimensions:
1. Confirmation that strains appear on EU authorized eligibility inventories;
2. Validation of complete, stamped, notarized English documentation packages;
3. Verification of claim-free, fully disclosed compliant labeling.
Pre-audit conclusion: Zero outstanding regulatory risks, with guaranteed seamless customs clearance.
1. 100% Resolution of All Regulatory Non-Compliance Risks
· Strains: Fully aligned with EU authorization standards, complete elimination of Novel Food import detention risks.
· Documentation: Full set of notarized English filings validated by both French legal counsel and customs authorities.
· Labeling: Dual EU & French regulatory compliance with zero prohibited claims, eligible for immediate end-product market launch.
1.
Unimpeded Customs Clearance & Accelerated Mass Production By late May 2026, the first shipment of 500kg Clostridium butyricum and 500kg Bacillus coagulans arrived in France with zero customs delays, mandatory sampling or financial penalties. The client rapidly completed national product registration and manufacturing, officially launching the new intestinal repair capsule line in late June with robust end-user sales performance and positive market feedback.
2.
3.
Long-Term Exclusive Strategic Partnership & Expanded Procurement Volume The client designated HiSiaddi as its sole regulatory-compliant raw material supplier, mandating HiSiaddi-led regulatory audits for all future probiotic procurement with projected threefold annual purchasing volume growth.
4.
Client Testimonial: “HiSiaddi is our regulatory lifeline for China supply chain market entry. Domestic manufacturers only prioritize production output with limited comprehension of EU regulatory frameworks, nearly derailing our entire product launch project. HiSiaddi possesses dual expertise in Chinese manufacturing quality control and granular EU/French probiotic regulatory requirements, resolving all three core regulatory bottlenecks involving strain eligibility, documentation and labeling within 15 days. They saved us from crippling fines and costly market launch delays—an authentic strategic partner with comprehensive expertise in high-end European market requirements.”
Regulatory compliance represents the primary critical risk for overseas mid-to-high-end clients sourcing Clostridium butyricum and Bacillus coagulans raw materials, with the EU market enforcing three non-negotiable compliance mandates:
1. Strain Eligibility Compliance: Clostridium butyricum requires formal Novel Food authorization; Bacillus coagulans must match strains listed on the EU QPS inventory with verifiable culture collection deposit numbers.
2. Documentation Compliance: Complete English, stamped and notarized filings covering manufacturing qualifications, safety declarations and third-party test reports are mandatory without exception.
3. Labeling Compliance: Prohibited “probiotic” terminology, full strain identifier disclosure and mandatory EU local responsible party listing are enforced.
Most domestic Chinese manufacturers prioritize production capacity while neglecting cross-border regulatory expertise, frequently resulting in client customs detention and blocked product launches. HiSiaddi’s core competitive advantage lies in its integrated dual capability spanning supply chain management and cross-border regulatory compliance: deep familiarity with Chinese manufacturing quality control protocols paired with granular expertise in EU/French probiotic regulatory frameworks, enabling targeted resolution of high-end client compliance demands, rapid completion of missing regulatory filings and comprehensive risk mitigation to facilitate seamless export of Chinese probiotic raw materials to premium European markets.
Contact HiSiaddi customer service for additional regulatory compliance consulting for Clostridium butyricum and Bacillus coagulans products.
+86-13120989737 
info@hisiaddi.com 
English
